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Lack of standardization in antibiogram (ABGM) preparation (the overall profile of antimicrobial suscep-
tibility results of a microbial species to a battery of antimicrobial agents) has not been addressed until recently.
The objective of this study was to analyze current antibiograms using the recently published NCCLS M39-A
guidelines for preparation of antibiograms to identify areas for improvement in the reporting of antibiogram
susceptibility data. Antibiograms from across the United States were obtained by various methods, including
direct mailings, Internet searches, and professional contacts. Each ABGM collected was analyzed using pro-
spectively defined elements from the M39-A guidelines. Additionally, seven quality indicators were also eval-
uated to look for the reporting of any atypical or inappropriate susceptibility data. The 209 antibiograms col-
lected from 149 institutions showed at least 85% compliance to 5 of the 10 M39-A elements analyzed. Clinically
relevant elements not met included annual analysis, duplicate isolate notation, and the exclusion of organisms
with fewer than 10 isolates. As for the quality indicators evaluated, unexpected results included the 7% of anti-
biograms that reported <100% vancomycin susceptibility for Staphylococcus aureus, 24% that had inconsistent beta-
lactam susceptibility for Staphylococcus aureus, 20% that reported <100% imipenem susceptibility for Escherichia
coli, and 37% that reported >0% ampicillin susceptibility for Klebsiella pneumoniae. These findings suggest that
antibiograms should be reviewed thoroughly by infectious disease specialists (physicians and pharmacists), clin-
ical microbiologists, and infection control personnel for identification of abnormal findings prior to distribution.
The NCCLS (now known as the CLSI [Clinical and Labo-
ratory Standards Institute]) defines an antibiogram (ABGM)
as an overall profile of antimicrobial susceptibility results of a
microbial species to a battery of antimicrobial agents (17),
which should reflect patient care needs along with the insti-
tution’s formulary (15). When properly prepared and inter-
preted, ABGMs are an important resource for healthcare
providers. While patient-specific cultures and susceptibility re-
ports are pending, the ABGM may guide empirical therapy
decisions based on likely pathogens and their probable suscep-
tibilities to anti-infectives available at the institution (6, 21, 24).
Clinicians and local infection control personnel use ABGM
data in monitoring resistance trends, identifying outbreaks,
developing quality improvement initiatives, and forming infec-
tion control policies and procedures (1, 6, 7, 8, 25). Microbi-
ology and laboratory personnel also use ABGMs as a quality
assurance measure for the Joint Commission on Accreditation
of Healthcare Organizations (6, 11, 19). Pharmacy and Ther-
apeutics committees use ABGM data when making anti-infec-
tive formulary decisions and establishing drug use policies (6).
The lack of standardization in the preparation and data
assimilation of ABGMs has not been addressed until recently,
though susceptibility testing has been standardized for years
(12, 18). Because of this lack of standardization, empirical
therapy selection based on ABGM data may be compromised.
Furthermore, the comparison of ABGM data between institu-
tions may be less meaningful when data have been summarized
using various methods. In an attempt to resolve these issues,
the NCCLS has published the M39-A guidelines. This docu-
ment provides recommendations on the collection, analysis,
and presentation of cumulative antimicrobial susceptibility test
data with the goal of guiding clinicians in the appropriate se-
lection of empirical therapy (17).
The objective of this study was to identify areas of improve-
ment in ABGM data presentation, which can ultimately im-
prove empirical anti-infective selection. Recent ABGMs from
different types of institutions from across the United States
were analyzed using the NCCLS M39-A published guidelines
on antibiogram development. Several quality indicators were
also evaluated for the reporting of any atypical or inappropriate
susceptibility data. It should be noted that analysis of specific
antibiotic resistance patterns were not a focus of this study.
MATERIALS AND METHODS
Antibiogram collection process. Direct mailings, professional contacts, and
Internet searches were used to collect ABGMs for 2000, 2001, and 2002 from
university-affiliated, state of Kansas, Kansas City metropolitan area, and various
community hospitals. Hospitals were identified using a University HealthSystem
Consortium database and an Internet search using http://www.yellowpages.com/.
During the fall of 2002, letters requesting antibiograms and demographic survey
completion were sent to 264 different institutions nationwide along with a pre-
addressed, postage-paid return envelope. Reminder cards were sent to nonre-
spondents. Recipient institutions were assured that their specific susceptibility
data would remain completely confidential. Additional ABGMs were collected
through professional contacts until March 2003.
An Internet search was conducted using the Google and Dogpile search
engines during winter 2003. Search terms included “antibiograms,” “hospital,”
“2001,” “2002,” “2003,” “university,” “susceptibility reports,” and “university
hospitals” in various combinations. Inclusion criteria included ABGMs during
the 2000, 2001, and 2002 calendar years reporting results from human isolates.
Demographic survey. The demographic survey included institution type, num-
ber of licensed beds, departments involved in publishing ABGM data, publica-
tion frequency, and availability of any electronic distribution methods. Incom-
plete surveys were completed using the institution’s Internet website or by
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telephone interview. The survey instruments were sequentially numbered prior
to mailing to identify nonrespondents.
Antibiogram analysis. Each ABGM was analyzed using prospectively defined
elements from the M39-A guidelines. The following elements were evaluated:
(i) methods of summarizing susceptibility data, (ii) reporting results as “percent
susceptible,” (iii) organisms’ morphological grouping, (iv) duplicate isolate no-
tation, (v) description of exact collection period, (vi) number of isolates for each
organism, (vii) reporting only organisms with greater than 10 isolates, (viii)
antimicrobial description (generic name, trade name), (ix) utilization of NCCLS
antimicrobial abbreviations, and (x) utilization of “dash” to describe susceptibil-
ity data not reported. For the purpose of analysis, frequency of publication was
also considered a prospectively defined element, for a total of 11 elements. Other
M39-A recommendations evaluated were based on institutional need. These
included separation of urine susceptibility data from nonurine susceptibility data,
separation of susceptibility data by hospital location (e.g., intensive care units),
and resistance trends descriptions (17).
Quality data indicators. Although data concerning antibiotic resistance pat-
terns were not a focus of this study, ABGMs were evaluated for atypical or
inappropriate susceptibility data to assess the quality of the data being reported.
These indicators were selected from the recent NCCLS M-100 performance
standards for susceptibility testing (17). These data included the following: (i) in-
consistent beta-lactam susceptibility for Staphylococcus aureus, (ii) vancomycin
susceptibility of less than 100% for S. aureus, (iii) Enterococcus spp. tested against
cephalosporins or trimethoprim-sulfamethoxazole, (iv) imipenem susceptibility
of less than 100% for Escherichia coli, (v) imipenem susceptibility for Stenotro-
phomonas maltophilia, (vi) less than 100% susceptibility to third-generation
cephalosporins for Haemophilus influenzae, and (vii) ampicillin susceptibility for
Klebsiella pneumoniae. In addition, we noted the frequency ABGMs report of
Streptococcus pneumoniae susceptibility.
Statistical analysis. Demographic information and preselected ABGM ele-
ments were descriptively compared and evaluated for statistical significance by
the use of bivariate analyses. Fischer’s exact or a 2 test was used when appro-
priate. Data were analyzed using SPSS for Windows, release 9.0 (Chicago, IL).
RESULTS
One hundred seven hospitals responded to letter requests,
yielding a 41% response rate. A total of 209 ABGMs were ac-
quired using all three collection methods, which represented
149 hospitals. Seventeen additional hospitals indicated that
ABGMs are not compiled at their institution. Fifty-seven per-
cent of the ABGMs were from 2001, 33% were from 2000, and
11% were from 2002.
Table 1 represents cross-tabulations for institutional demo-
graphics based on hospital size. Antibiograms from large hos-
pitals (250 beds) represented 61% of the sample, while 59%
of institutions were community hospitals. Over one-third of the
institutions (36%) distribute ABGMs electronically (intranet,
22%; Internet, 14%).
Antibiogram evaluation. Fig. 1 represents the frequency of
analyzed ABGMs meeting the 11 predefined M-39A elements.
Over 85% of the ABGMs met at least seven of the elements
evaluated. Only 1 ABGM of the 209 evaluated met all 11 ele-
ments. Table 2 represents cross-tabulations for the 11 prese-
lected M39A ABGM elements by hospital size.
TABLE 1. Demographics by institution
Parameter
No. of ABGMs from
hospitals with bed size of: P value
(2 test)
0–50 51–250 250 Total (%)
No. of institutions 23 51 92 166 0.072
No. of institutions with
ABGMsa
9 49 91 149
Type of Institution
Academic 1 2 54 57 (34.3) 0.001
Community 19 44 35 98 (59.0)
Veterans Administration 0 4 1 5 (3.0)
Other 3 1 2 6 (3.7)
ABGM compiled by:
Laboratory personnel 8 41 65 114 (76.5) 0.139
Pharmacy personnel 0 0 4 4 (2.7)
Laboratory and pharmacy
personnel
0 8 16 24 (16.1)
Other 1 0 6 7 (4.7)
Electronic reporting
No 5 26 35 66 (55.5) 0.003
Yes; intranet 2 8 22 32 (26.9)
Yes; Internet 0 1 20 21 (17.6)
a Evaluated in analysis.
FIG. 1. Frequency of analyzed ABGMs meeting the 11 predefined
M-39A elements.
TABLE 2. Summary of data by ABGM
Parameter
No. of ABGMs from hospitals
with bed size of:
0–50 51–250 250 Total (%)
Summarized data presentationa 9 68 122 199 (95.2)
Organisms separated by morphology 10 63 114 187 (89.5)
Reported as % susceptible 10 73 120 203 (97.1)
Duplicate isolate notation 2 5 17 24 (11.5)
ABGM frequency
More than annually (12 mo) 1 4 20 25 (16.8)
Annually 6 44 70 120 (80.5)
Less than annually (12 mo) 2 1 1 4 (2.7)
Collection period description
(i.e., mo and yr)
5 52 94 151 (72.2)
No. of isolates reported 11 73 119 203 (97.1)
Less than 10 isolatesb 6 37 42 85 (40.7)
Name used in antimicrobial
agent description
All generic 11 56 99 166 (79.4)
All generic and all brand 0 3 6 9 (4.3)
All generic and some brand 0 4 5 9 (4.3)
Some generic and some brand 0 11 14 25 (12.0)
Antimicrobial abbreviations used
NCCLS recommended 1 14 7 22 (10.5)
Other 1 6 30 37 (17.7)
Presentation of susceptibility
data not reported
Dash 0 6 20 26 (12.4)
Blank 6 48 75 129 (61.7)
Other method (e.g., shading,
asterisk, etc.)
5 20 29 54 (25.8)
Total no. of ABGMs 11 74 124 209
a Defined as data presented in tabular form.
b Defined as the number of ABGMs with at least one organism reported with
less than 10 isolates (n  203).
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Susceptibility data presentation. The NCCLS recommends
that final verified susceptibility results be reported on ABGMs
(17). In this study, computer-generated, raw susceptibility
summaries were not classified as “final, verified results” and
represented only 5% of the entire sample.
Antibiogram methodology. The NCCLS advocates the use
of “percent susceptibility” for each data box, clarification
of where the isolates came from (i.e., use of duplicates), and
description of the collection period (17). Reporting the sus-
ceptibility data as “percent susceptible” for each organism-
antimicrobial agent combination was the most commonly
used method (97%). Additionally, seven quality indicators
were also evaluated to look for the reporting of any atypical
or inappropriate susceptibility data.
Isolates from the same patient should be excluded from
ABGMs for a 1-year time period (17). This recommendation
could not be evaluated; therefore, we evaluated ABGM doc-
umentation of inclusion or exclusion of duplicate isolates. Only
12% of ABGMs documented how duplicates were managed.
Most ABGMs are compiled on an annual basis, as NCCLS
recommends. They generally included the dates (month and
year) for the collection period (72%). Of those, 70% reflected
calendar years (January through December). Others periods of
time included July to June and May to April.
Morphological grouping. Most ABGMs separated organ-
isms by morphology (90%), as recommended, with less than
4% reporting fungal susceptibility information. The remainder
(10%) listed organisms alphabetically or by prevalence of oc-
currence.
Number of isolates. The inclusion of the total number of
isolates collected for each organism is recommended along
with the inclusion of data only for those organisms with 10 or
more isolates (17). Ninety-seven percent of ABGMs reported
the number of isolates tested per organism-antimicrobial com-
bination. Interestingly, 42% of ABGMs contained susceptibil-
ity data for organisms with fewer than 10 isolates. As shown
in Fig. 2, many of these were clinically uncommon species or
urine isolates.
Antimicrobial description. The M39-A document vaguely
recommends the use of complete antimicrobial names (17).
Generic nomenclature was used most often (88%), followed
by a mixture of some generic and some brand names (12%).
Combination products (e.g., piperacillin-tazobactam) were
most commonly implicated when ABGMs utilized brand
names. The NCCLS recommends that when abbreviations are
used for ABGMs, they should either agree with abbreviations
used on patient susceptibility reports or utilize those listed in
Appendix F of the M39-A document (17). Since it is not pos-
sible to ascertain abbreviation congruency between patient sus-
ceptibility reports and individual ABGMs, those contained in
the M39-A document were the basis for this assessment. Twen-
ty-eight percent of ABGMs contained abbreviations, and of
those, only 37% used the NCCLS abbreviations.
Data not reported. Use of a dash in each ABGM data box
when a drug is either not tested at that institution or when it is
known to be clinically ineffective is recommended in the M39-
A guidelines (17). Our data show that only 12% of ABGMs
utilized the dash method, 25% used another method, and the
remainder simply left the data box blank.
Other M39-A recommendations based on institutional need.
The guidelines recommend that selectively tested antibiotics
should be noted in some manner (e.g., footnotes) (17). Forty-
seven percent of ABGMs separated urine isolates from nonu-
rine isolates. Susceptibility information may be separated by
specialty care areas, such as intensive care units or outpatient
areas within the institution, to allow for more meaningful com-
parisons between like units and the overall institution ABGM
(17). A few ABGMs had separated specific location suscepti-
bility information into intensive care units (n  20) and out-
patient areas (n  30). To assist clinicians with interpreting
significant ABGM changes from year to year, institutions can
provide a summary of major resistance trends in a variety of
ways, such as with tables or graphs (1). Over 14% of ABGMs
reported resistance trends. Various methods included the use
of brief summaries, graphs, upward- and downward-pointing
arrows in the data boxes, or numbers in boldface or nonbold-
FIG. 2. Organisms with fewer than 10 isolates reported.
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face type. A couple of institutions distributed a brief letter with
each new ABGM.
Quality data indicators. Overall, 14.3% of ABGMs included
unusual results, based upon the seven prospectively defined
quality indicators assessing unusual results and indicating un-
verified ABGMs. Table 3 summarizes the results for these data
quality indicators by institution size. The number of ABGMs
assessed for each quality indicator varied widely, since not all
ABGMs included results for each organism-antimicrobial com-
bination evaluated.
Twenty-four percent of ABGMs reported inconsistent sus-
ceptibility rates for S. aureus across the beta-lactam class, spe-
cifically the penicillinase-resistant penicillins, cephalosporins,
and carbapenems. Of further interest, 7% of the study ABGMs
(13 of 198) reported less than 100% vancomycin susceptibility
(range, 98 to 99% susceptible) for S. aureus. Few ABGMs (3
of 198) reported susceptibility data for Enterococcus spp. to
cephalosporins and trimethoprim-sulfamethoxazole. Despite
the widespread availability of national surveillance data which
routinely characterize the susceptibility trends for pneumococ-
cus, only 20% of ABGMs included susceptibility data for this
pathogen.
Of ABGMs that reported E. coli, 20% showed less than
100% imipenem susceptibility (range, 93 to 99% susceptible),
while 43% reported S. maltophilia as having susceptibility to
imipenem (range, 2 to 11% susceptible). Thirty percent (10 of
33) of ABGMs reported less than 100% susceptibility (range,
75 to 97% susceptible) of H. influenzae isolates to broad-spec-
trum cephalosporins. Ampicillin showed susceptibility (range,
1 to 19% susceptible) to K. pneumoniae in 49% of ABGMs.
DISCUSSION
In an era of antimicrobial misuse, increasing anti-infective
resistance, and reduced emphasis on antibiotic development by
pharmaceutical manufacturers, the need for reliable, accurate
ABGM data to guide appropriate antibiotic selection is critical
(9, 20, 26). The recent publication of the first approved stan-
dards for cumulative susceptibility data presentation under-
scores the importance of these documents and their use in
clinical practice. A couple of survey studies evaluate ABGM
preparation but, to our knowledge, this study is the first of its
size to evaluate actual ABGMs within the context of these
standards (4, 8).
Perhaps the most interesting finding came from the evalua-
tion of final, verified ABGM data, as done by evaluating eight
separate quality indicators from the M-100 performance stan-
dards (18). These surrogate markers represent ABGM validity.
With only eight documented cases of vancomycin-intermediate
S. aureus (VISA) and three documented cases of vancomycin-
resistant S. aureus (VRSA) in the United States (3, 5, 13), the
7% of ABGM analyzed with less than 100% vancomycin re-
sistance for S. aureus lead us to believe either that the suscep-
tibility data had not been verified at the institution level or that
VISA or VRSA is more common than the published reports
indicate. None of the institutions we evaluated were the insti-
tutions with published VISA/VRSA cases in the literature.
Inconsistent beta-lactam susceptibilities for S. aureus may lead
inexperienced clinicians to choose an inappropriate empirical
regimen.
Although Halstead et al. reported that 90% of their respon-
dents had a system in place to alert staff of atypical results (8),
our findings indicate that many of these ABGMs may not have
been thoroughly screened prior to distribution, since 14% of
ABGMs had unusual susceptibility results. It is recommended
that microbiology personnel or other clinicians review draft
versions of ABGMs prior to distribution (10).
While the ABGM can be an important tool to increase
awareness of hospital resistance patterns, study data revealed
that a substantial number of small hospitals do not prepare
ABGMs. This lack of ABGM preparation may be due to the
fact that these small institutions have limited resources avail-
able or that their cultures are sent to outside laboratories,
given that there is low demand for this service (23).
The NCCLS recommends that ABGMs be prepared on an
annual basis to allow for proper trend interpretation without
confounders of seasonal variations (17). Although others con-
tend that more frequent analysis of susceptibility data can
reveal early identification of resistance trends (15), the results
of our study show that the majority of institutions report cu-
mulative susceptibility data on an annual basis. Also, there was
no consistency with dates used to label antibiogram docu-
ments. For example, a “2002” label on an antibiogram could
refer to the actual collection date or the current year of re-
lease, which often leads to confusion by clinicians using these
documents.
As expected, microbiology laboratory personnel compiled
the majority of ABGMs; however, pharmacists were involved
in the preparation process at 19% of institutions. Our findings
underscore the value of using a multidisciplinary approach
(physicians, infection control personnel, microbiologists, phar-
macists) in reviewing antibiogram data prior to publication to
avoid reporting misleading or suspicious susceptibility infor-
mation. Also, with the increased use and accessibility of tech-
nology, it is not surprising that over 35% of institutions report
their ABGMs on hospital Internet or intranet sites. It is advis-
able to provide an annual summary that highlights current
susceptibility information, as several institutions in this study
have done. This can assist clinicians with understanding insti-
tutional shifts in susceptibility from one reporting period to





No. of ABGMs from





S. aureus Beta-lactam (inconsistent) 3 19 27 49/201
Vancomycin (100) 0 10 3 13/198
Enterococcus spp. Cephalosporins 1 2 0 3/198
Trimethoprim-sulfa-
methoxazole
2 1 0 3/198
E. coli Imipenem (100) 3 13 18 34/170
S. maltophilia Imipenem (0) 1 2 14 17/39
H. influenzae Broad-spectrum ceph-
alosporins (100)
0 4 6 10/33
K. pneumoniae Ampicillin (0) 3 27 48 78/160
Total number
of ABGMs
11 74 124 209
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another and can be helpful for making empirical antibiotic de-
cisions.
Many practitioners are completely unaware of how duplicate
isolates from the same patient can skew susceptibility data on
the antibiogram. Frequently, such duplicate isolates falsely el-
evate resistance rates. This has recently been addressed in both
the literature and by the NCCLS (10, 14, 16, 22, 27), yet only
12% of ABGMs analyzed included some notation of how du-
plicate isolates from the same patient were managed during the
compilation of susceptibility data. The proportion of institu-
tions that report only nonduplicate isolates may be higher than
is actually reported on ABGMs (7). Furthermore, it is appar-
ent that to fully comply with the NCCLS duplicate isolates
recommendation, laboratory information systems need to be
modified to facilitate the removal of duplicate isolates, which is
a tedious and time-consuming process when done manually
(10, 16).
Nearly all ABGMs reported the number of isolates repre-
sented; however, 41% reported susceptibility information on
less than 10 isolates. The NCCLS recognizes that this number
of isolates is an arbitrary number; however, it was chosen to
assure that a low sample size does not mislead practitioners.
The question is whether small numbers will negatively influ-
ence susceptibility conclusions or would provide insight into
the susceptibility data of less prevalent organisms (e.g., fungal
pathogens). The small sample size of isolates reported also
could influence many smaller hospitals in electing not to pre-
pare ABGMs or to prepare them infrequently.
The use of complete antimicrobial names, NCCLS-defined
abbreviations, or abbreviations used on patient reports is rec-
ommended. We interpreted this recommendation, regarding
“complete antimicrobial names,” as meaning complete generic
names, which follows the pattern exhibited throughout the
M-39A document. The use of brand names for combination
products could be due to spatial concerns on the ABGM or
ease of recognition of brand names. Because the abbreviations
for anti-infectives that were used on patient reports were un-
available, we analyzed this recommendation based solely upon
the M-39A document. Therefore, the full implication of the
recommendation is difficult to assess in the present study.
In our analysis, we discovered that institutions most fre-
quently deviated from the guidelines when indicating that an
antibiotic-pathogen combination was neither reported nor
tested. With only 12% of respondents using the dash meth-
od, perhaps any method denoted on the ABGM, other than
leaving blank data boxes, should be an acceptable alterna-
tive. Additionally, the use of reporting results from selectively
tested isolates, specific locations, or resistance trends may be
interesting, yet their use may not be feasible for smaller insti-
tutions based on need and quantity of isolates tested.
Our study contained several potential limitations. The most
notable was that all conclusions were established based on
ABGM evaluation without detailed knowledge of each insti-
tution’s hospital policies and procedures. Furthermore, the
M39-A guidelines contain approximately 40 recommendations,
many of which could not be evaluated by inspecting only the
antibiogram documents. For example, the recommendations
regarding data analysis systems, patient demographic informa-
tion, specimen identification and specifications, and antimicro-
bial susceptibility testing methods could not be assessed by
the methods outlined. Additionally, readability may have been
hampered in some cases by the access to photocopied versions
of some of the ABGMs. The use of multiple ABGMs from the
same institution could have influenced our study results. It is
also possible that respondents who returned more than one
ABGM were more interested in the process and/or had better
access to published ABGMs data than other respondents.
We included these multiple ABGMs in the analysis because
ABGM preparation tends to evolve, and we believed that other
institutions could learn from the changes that are made from
year to year.
Despite these limitations, we and other organizations recog-
nize the importance of ABGMs as a clinical tool. In 2002,
the Centers for Disease Control and Prevention began pro-
moting its latest campaign, “12 steps to prevent antimicrobial
resistance among hospitalized adults” (2). The importance of
ABGM data is featured in Step 6, “Use local data.” Specifical-
ly, the campaign asks that healthcare professionals know their
antibiogram, formulary, and patient population. In addition,
the Joint Commission on Accreditation of Healthcare Organi-
zations recognizes the ABGM as a quality assurance measure
for clinical laboratories and therefore as a fulfillment of Stan-
dard IM.8 (6, 11).
Given the emphasis that government agencies, accredita-
tion organizations, and the medical literature have placed
on antimicrobial susceptibility patterns and inappropriate
use of antimicrobials, it is evident that ABGMs have under-
gone scrutiny. The lack of standardization limits the versatility
of ABGMs across various areas of healthcare, including em-
pirical antimicrobial selection, ABGM surveillance, and assis-
tance in hospital and public health policy. Adoption of the
M39-A guidelines for preparation of antibiogram data should
improve the quality, standardization of reporting, and inter-
pretation of results by infectious disease specialists along with
microbiology and infection control personnel.
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